Science & Health Powering Your Cells
FORZINITY, formerly SS-31, received accelerated FDA approval for Barth syndrome. It is a landmark—not a blanket endorsement for anti-aging, fatigue or performance use.
Approval covers Barth syndrome in patients weighing at least 30 kg; a confirmatory trial is still required.
Signals from the lab and clinic, labeled by the strength of evidence—not the size of the promise.
A protein-binder system reported in Nature directed donor mitochondria to selected diseased cell types and improved survival in cell and animal models. Precision delivery could address one of mitochondrial transplantation’s hardest engineering problems.
Nature analysis ↗A molecular disguise helped transplanted mitochondria enter cells with defective organelles. Human efficacy and dosing remain untested.
Nature report ↗The first published outcomes found the children healthy at birth and meeting milestones. Long-term and tissue-specific risks remain open.
Read the findings ↗In a Friedreich’s ataxia model, donor-derived immune cells transferred healthy mitochondria to failing cells and partially eased symptoms.
Read the report ↗Small studies in cardiac shock, stroke and inflammatory myopathy report early safety signals. None yet proves efficacy in a Phase 2 or 3 trial.
Review the evidence ↗Six interventions frequently discussed in mitochondrial and longevity clinics—separated into mechanism, human evidence and real-world risk.
Biological plausibility is not the same as a demonstrated clinical benefit. The summaries below distinguish established uses from off-label or unapproved claims, with extra weight on controlled human evidence.
TPE / plasmapheresis · established medical procedure; healthy-aging use is off-label
An apheresis machine separates blood cells from plasma; the plasma is discarded and replaced, usually with 5% albumin. A session generally takes 2–3 hours, and one plasma-volume exchange removes roughly 60% of circulating macromolecules. The proposed mitochondrial benefit is indirect: removing inflammatory mediators, autoantibodies, oxidized lipids and age-elevated proteins may reduce oxidative stress that impairs mitochondrial function.
TPE has decades of established use for conditions such as Guillain–Barré syndrome, myasthenia gravis and thrombotic thrombocytopenic purpura. Mouse plasma-dilution studies improved tissue repair and cognition. A 42-person randomized, sham-controlled 2025 study found mid-trial biological-age shifts—largest with TPE plus IVIG—but no significant group differences at later follow-up. A separate 2025 plasmapheresis trial found no epigenetic rejuvenation. The only direct human mitochondrial-endpoint study was small, non-randomized and limited to acute fatty liver of pregnancy.
Reported risks include citrate-related hypocalcemia and tingling, low blood pressure, fatigue, medication removal, coagulation changes, and catheter-related infection or thrombosis. Albumin replacement lacks clotting factors. TPE has not been shown to extend lifespan or durably improve mitochondrial function in healthy people; epigenetic clocks remain surrogate markers.
Extracorporeal blood oxygenation and ozonation · not FDA-approved
Blood moves through a continuous extracorporeal circuit, contacts a low-concentration oxygen–ozone mixture across a filter membrane, and returns through a second line. Sessions are commonly described as 60–90 minutes. Ozone disappears quickly, leaving reactive products such as 4-HNE. The hypothesis is mitohormesis: a controlled oxidative signal may activate Nrf2 defenses, encourage mitochondrial biogenesis, and alter red-cell oxygen unloading or microcirculation.
Low-dose ozone has produced transient mitochondrial changes in cell models, returning to baseline by 48 hours. The only controlled clinical trial we found randomized 28 people with peripheral artery disease to EBOO or IV prostacyclin; skin lesions and symptoms improved more with EBOO, but vascularization did not. It was small, single-center, developer-run and has not been independently replicated. No controlled human trial has measured mitochondrial or bioenergetic outcomes.
G6PD deficiency is an absolute contraindication because of hemolysis risk. Other concerns include gas embolism, infection or clotting in the circuit, and reported neurologic events; toxic hyperthyroidism, platelets below 50,000 and severe cardiac instability are also cited contraindications. U.S. regulation describes ozone as a toxic gas with no known useful medical application. Marketing claims substantially exceed the evidence.
Intravenous polyenylphosphatidylcholine · not FDA-approved
Plaquex is a slow IV infusion of soybean-derived polyenylphosphatidylcholine. Phosphatidylcholine is a major structural lipid in biological membranes, while mitochondrial membrane integrity is essential to energy production. A 2026 Nature Communications study linked age-related loss of phosphatidylcholine synthesis to mitochondrial-network disruption and restored mitochondrial integrity in worms and metabolic resilience in human cell culture. That supports the pathway—not IV Plaquex in people.
There are no large modern randomized trials showing that IV phosphatidylcholine clears arterial plaque, improves cardiovascular outcomes or treats mitochondrial dysfunction. Frequently repeated percentage claims and two clinic-cited journal studies could not be verified in primary literature. More rigorously engineered phospholipid/apoA-I infusion programs such as MDCO-216 and CER-001 also failed to demonstrate plaque regression, which argues for caution when translating membrane biology into a vascular claim.
Reported concerns include vein irritation or thrombophlebitis, low blood pressure if infused too quickly, nausea, diarrhea, rare allergy, a mild anticoagulant effect and soy exposure. The FDA’s 2010 warnings involved cosmetic phosphatidylcholine/deoxycholate “lipodissolve” injections—not this infusion protocol—but underscore that phosphatidylcholine products and claims are not automatically approved. The mitochondrial hypothesis is interesting; clinical evidence for the marketed IV therapy is weak to absent.
Featuring InhaleH2 · consumer and clinic device · no documented FDA clearance
Molecular hydrogen (H2) is inhaled as a low-concentration gas mixture. The field began with a 2007 Japanese study showing selective reduction of highly cytotoxic hydroxyl radicals while sparing signaling oxidants; peroxynitrite reduction is also proposed. Preclinical work reports stabilization of mitochondrial membrane potential, improved ATP handling, mitophagy, and Nrf2/ARE antioxidant signaling. A single 2025 study proposed a different model: H2 transiently suppresses complex III through its Rieske iron-sulfur protein, triggering a protective mitochondrial unfolded-protein response. That hormesis hypothesis is new, preclinical and not yet independently established.
Tyler W. LeBaron, PhD—not an MD—is founder of the nonprofit Molecular Hydrogen Institute, holds a PhD in animal physiology, and co-authored the 2025 Rieske paper. He is also InhaleH2’s Chief Scientific Officer, a commercial conflict that belongs beside his scientific claims. Co-inventor Alex Tarnava is an entrepreneur, hydrogen-tablet inventor and manufacturer who describes himself as having no formal scientific training. Their $6,499 InhaleH2 uses SPE-PEM water electrolysis with platinum-coated titanium electrodes. The company claims 99.99% H2 purity; a dial/app sets inspired H2 from 0–4% in 11.6–12 L/min airflow through a one-way mask and reservoir bag. It is sold direct to consumers in 110V and 220V versions and through clinic channels. “Third-party tested” is claimed, but no report or certifying body was located.
Human results are small and mixed. In Japan, the underpowered HYBRID II cardiac-arrest trial missed its primary neurological endpoint but favored H2 on secondary survival measures; Parkinson’s moved from a positive 2013 water pilot to a larger 2018 multicenter null trial and a null 2021 inhalation pilot. A Chinese multicenter COPD trial improved symptom scores but not lung function, blood gases or oxygen saturation. A South Korean radiotherapy study (Kang et al., 2011; n=49) used oral hydrogen-rich water—not inhalation—and improved quality of life, not tumor response; it does not validate this device or delivery route. Trials report no H2-attributed serious adverse events, but dedicated human safety trials and long-term data are absent. Hydrogen’s lower flammability limit in air is 4%; the device is engineered not to exceed 4%, making handling and ventilation consequential. No FDA approval exists for H2 therapy, and no clearance for this device was found. Japan’s “Advanced Medical Care B” use is a trial designation, not full approval. There are no human longevity trials.
HBOT · pressurized oxygen · motor-control evidence is condition-specific and mostly off-label
Clinical HBOT usually delivers 100% oxygen at 1.5–3.0 atmospheres absolute (ATA). Intermittent hyperoxia may trigger a relative-hypoxia signal between sessions, activating HIF-1α/VEGF pathways, while SIRT1–PGC-1α–TFAM signaling may support mitochondrial biogenesis. Animal and small human studies also report antioxidant, neuroinflammatory and neuroplasticity signals. These are plausible mechanisms—not proof of better motor control or durable mitochondrial repair in people.
A 2013 Israeli randomized crossover study in chronic stroke used 40 sessions at 2.0 ATA and reported neurologic, daily-function and SPECT improvements, but lacked a sham chamber. Parkinson’s meta-analyses covering 13–16 mostly Chinese studies report modest motor-score gains alongside sleep and cognition signals; protocol heterogeneity and variable study quality limit confidence. In healthy adults, a 1.4-ATA HIIT study increased muscle PPARGC1A expression without improving V̇O₂peak beyond exercise alone.
Israel’s Shamir/Sagol group leads the human aging and stroke literature, including a 63-person older-adult RCT with a modest VO₂max gain after 60 sessions; several authors disclosed AVIV Scientific ties. China supplies much of the Parkinson’s evidence. Taiwan has contributed mouse-mechanism work, Belgium the pulsed-hyperoxia model, and Canadian reviews remain skeptical of sports-performance claims. Larger independent, multicenter and sham-controlled trials are still needed.
No human trial shows lifespan extension, healthy-aging reversal or improved motor performance in healthy people. Stroke, Parkinson’s and TBI findings cannot be generalized to wellness use. Biomarkers such as telomere length and mitochondrial-gene expression are surrogate outcomes. Dose matters: most positive clinical studies used roughly 2.0–2.5 ATA; low-pressure wellness chambers around 1.3 ATA should not inherit those claims.
HBOT has recognized medical uses including decompression sickness, carbon-monoxide poisoning, selected problem wounds and delayed radiation injury; aging, stroke recovery, Parkinson’s and athletic recovery are not FDA-cleared indications. Untreated pneumothorax is an absolute contraindication. Risks include ear or sinus barotrauma, temporary vision change, oxygen-toxicity seizure, lung injury and fire in oxygen-enriched settings. Accredited medical facilities and clinical screening matter.
OneHypeWellness ↗ is a commercial manufacturer/seller offering One Hyperbaric “smart” chambers. Its site does not publish operating pressure in ATA, so whether trial dosing applies cannot be determined. Claims including “world’s only smart chamber,” “reverse cellular aging” and “1500% more oxygen” were not backed by peer-reviewed trials of its specific devices in our review. The site documents what the company offers and claims; it is not efficacy evidence.
Red/NIR photobiomodulation and far-infrared heat · related marketing, different biology
Red light (~620–700 nm) and near-infrared (~700–1100 nm) are non-thermal photobiomodulation bands. The leading—but debated—mechanism is photon absorption by mitochondrial cytochrome c oxidase, nitric-oxide release, restored electron transport and short-lived ROS signaling that can influence ATP production, Nrf2 defenses and PGC-1α/TFAM biogenesis. Response is biphasic: too little may do nothing, while too much can inhibit.
Trials suggest modest, indication-specific benefits, not a general mitochondrial “recharge.” A 2025 meta-analysis of 19 exercise studies (672 participants) found low-certainty reductions in soreness and better 24-hour performance when PBM was used before exercise; other reviews and a small 2025 athlete trial found no meaningful strength, swelling, range-of-motion or soreness advantage. Hair-growth devices have the clearest established consumer indication. Brain, cognition and dry-AMD studies remain small or investigational, with mixed outcomes and unresolved risks.
PBM work spans North American exercise and cognition pilots, European musculoskeletal studies, and multinational LIGHTSITE retinal trials. Small dementia and mild-cognitive-impairment trials report encouraging short-term signals, but reviews cannot pool the heterogeneous protocols confidently. Wavelength, irradiance, fluence, pulsing, timing and treatment site differ substantially, making results difficult to transfer from one device or use case to another.
Far-infrared (~3 µm–1 mm; sauna emitters often ~5–20 µm) is absorbed mainly as heat. It does not use the red/NIR cytochrome-c-oxidase mechanism. Small, often Japanese “Waon therapy” studies report vasodilation, blood-pressure, endothelial and heart-failure signals, but mitochondrial relevance is indirect through perfusion and oxidative-stress changes. There are no established direct human mitochondrial endpoints, and “detox” claims are not supported.
No human study establishes durable mitochondrial-function improvement, longevity extension or “cellular-age reversal.” PBM is generally well tolerated, but can cause warmth or redness; use wavelength-rated eye protection and seek medical clearance with photosensitizing drugs, porphyria, lupus, cancer near the treatment site, pregnancy or retinal disease. Far-infrared heat adds dehydration, hypotension and cardiovascular stress. Many consumer devices are FDA 510(k)-cleared only for narrow uses such as temporary pain relief, circulation, wrinkles or hair growth—clearance is not broad disease-treatment approval.
One Hype’s One Light line ↗ includes SmartWave Prime and Nova beds using red + near-infrared light only; the company does not offer far-infrared therapy. One Hype is a commercial manufacturer/seller. Its “reverse cellular aging” language and broader performance claims were not backed by peer-reviewed trials of these specific beds in our review. Company pages support product descriptions and claims—not efficacy.
No single test diagnoses every mitochondrial disorder. Expert workups combine genetics, metabolites, clinical findings and—in selected cases—tissue-level functional analysis. Availability and specimen requirements vary by country and laboratory.
Full mitochondrial-genome NGS with heteroplasmy and deletion analysis. A second tissue may be needed when blood is negative.
Example: Mayo MITOP ↗Most mitochondrial proteins are nuclear-encoded. Multigene panels or exome sequencing can find causes missed by mtDNA testing.
Example: 221-gene panel ↗Respiratory-chain enzyme activity, COX/SDH histochemistry and sometimes high-resolution respirometry assess function directly.
Consensus guidance ↗Useful first-line metabolic clues with clinical reference ranges—but nonspecific, and never a stand-alone diagnosis.
Example: metabolite panel ↗MITOP whole-mtDNA NGS accepts blood, muscle, nerve and other validated specimens. MMPP plasma metabolites is performed under CLIA requirements but is not FDA-cleared—typical for a laboratory-developed test.
Test definition ↗National test pathways include whole mtDNA sequencing (R300.1), rearrangement testing and nuclear analysis. Choice of blood, urine or muscle depends on phenotype and heteroplasmy.
UK best-practice guide ↗Whole-mitochondrial-genome NGS is listed for EDTA blood, saliva, urine, muscle/liver and CVS. Access is through clinical referral; authorization and funding vary.
Service listing ↗The molecular diagnostics program lists mitochondrial genome sequencing and depletion/integrity analysis for physician use across Canada.
Program details ↗Seahorse and Oroboros platforms are powerful research or specialist-lab instruments, not validated direct-to-consumer diagnoses. Wellness kits claiming to score “mitochondrial age” or prescribe treatment should show analytical validity, clinical validity and utility—not just a compelling dashboard. Read our IGL test deep dive ↓
The supplied 2023 sample report is not one test so much as a suite of blood-cell assays: ATP handling, mitochondrial membranes, antioxidant defenses, nutrient cofactors, DNA adducts and a 24-substance cellular-toxin screen. The biology behind those targets is real. Whether IGL’s specific measurements reliably diagnose disease or direct treatment is not established.
IGL Labor GmbH in Wittbek, Germany, describes itself as an integrative “medical epigenetics” laboratory. Its classic panel asks whether blood cells can make and move ATP, whether mitochondrial membranes appear stressed, and whether antioxidant, detoxification and nutrient systems look constrained. These are the components shown in the supplied sample report and described in IGL’s own test catalog ↗.
Measures cellular ATP with native and added magnesium, ADP-to-ATP conversion, and the claimed movement of ADP into and ATP out of mitochondria. In plain language: does the battery charge, and can its power get out?
Attempts to read the electrical and chemical gradient that powers ATP synthase. IGL’s exact public method for these measurements could not be verified independently.
Looks at cardiolipin synthesis and membrane phospholipids, plus cytochrome-c-oxidase–related signals. Cardiolipin is essential inner-membrane scaffolding; the report’s clinical interpretation remains investigational.
Reports chemicals claimed to be covalently attached to leukocyte DNA and links them to genomic locations. This is not the same as proving that an exposure caused a disease or changed a gene’s activity in the patient.
Profiles superoxide-dismutase activity across cytoplasmic, mitochondrial and extracellular compartments—an attempt to map defenses against superoxide and their mineral cofactors.
GST and glutathione-peroxidase measurements aim to assess toxin conjugation and peroxide clearance. These pathways matter biologically; the panel’s treatment utility has not been independently established.
Examines proteins involved in binding mercury and cadmium and in handling zinc and copper. An abnormal research result is not, by itself, proof of heavy-metal poisoning.
Red-cell NAD is used as a niacin-status signal; carnitine supports fatty-acid transport into mitochondria; fructose-phosphate markers are framed as a window on metabolic or liver stress.
IGL calls iEC “intracellular Electrical Capacity.” Lymphocytes are isolated from blood, and the lab attributes an electrical/capacitive signal to each target substance. The iEC-24 report takes four measurements, then displays an arithmetic mean and mean absolute deviation in nmol/l. A publicly available redacted report ↗ prints these four lab-defined bands:
Standard 24: aflatoxin B1, aluminium, antimony, benzoquinones, BPA, cadmium, CTABr, chlorotoluenes, chromium VI, diesel exhaust gases, formaldehyde, fumonisin B1, fungisterol A, glyphosate/AMPA, lead, lindanes and isomers, inorganic mercury, organic mercury, nickel, nitrosamines, organophosphates, phthalates, polybrominated biphenyls and triclosan.
Interpret carefully: the report says its reference values are validated only for lymphocytes. No peer-reviewed validation of the iEC method itself was found in our review, and a clinic document’s claim of 98% precision was not backed by a method-validation paper. A colored band should not be treated as proof of exposure, toxicity or a need for detox treatment.
The ATP-profile idea traces to work by Sarah Myhill, Norman Booth and John McLaren-Howard. Their 2009 study of 71 ME/CFS patients and 53 controls reported a strong relationship between a composite mitochondrial-energy score and disability (P<0.001). Read the original paper ↗
The strongest independent check points the other way. In 2019, teams in Newcastle and Oxford replicated the protocol in 10 patients and 13 controls and found no difference in any score component (p ≥ 0.059). A 24-hour processing delay significantly changed many readings. The authors concluded the test lacked the reliability and reproducibility required for an ME/CFS diagnostic test. Read the replication in Scientific Reports ↗
ATP energetics, cardiolipin, NAD, carnitine, SOD, glutathione and metallothionein all have established roles in cell biology.
That IGL’s exact blood-cell assays measure those systems reproducibly enough to guide individual clinical treatment.
The ATP profile as a diagnostic test for ME/CFS; the 2019 independent replication did not reproduce the original signal.
Promising mechanisms, before the headlines outrun the data.
The study is testing safety and tolerability in healthy adults. Patient benefit has not yet been established.
Trial report ↗The USP30 inhibitor is designed to enhance mitophagy. Early studies confirmed brain penetration; proof-of-mechanism data are pending.
Program update ↗A 2026 research grant supports Dr. James McCully’s work on mitochondrial transplantation for Duchenne muscular dystrophy.
Announcement ↗Claims, loopholes and setbacks that deserve the same attention as breakthroughs.
Animal and observational human studies have generated attention, but there is no completed human intervention trial proving performance, fat-loss or longevity benefits. A 2026 advisory committee recommendation about compounding is not FDA approval.
Understand the regulatory status ↗Elamipretide’s accelerated approval is limited to Barth syndrome; prior primary-mitochondrial-myopathy endpoints were not met. Compounded SS-31 is not approved.
Approval history ↗Human work remains Phase 1, pilot or case-series evidence. Dosing, durability, repeat-dose immunity and arrhythmia risk remain unresolved.
Review ↗Marketing language can blur wellness and diagnosis. Before acting, ask whether the assay and the claimed interpretation were independently validated.
Lancet commentary ↗